Cyclosporine on Day Zero as Prophylaxis for Cytokine Release Syndrome
Status:
Recruiting
Trial end date:
2023-02-17
Target enrollment:
Participant gender:
Summary
Phase II, randomized controlled, unblinded clinical trial. Will evaluate whether the
administration of oral cyclosporine started on day 0 of transplantation is effective in
reducing the incidence of cytokine release syndrome (CRS) in patients who receive an
outpatient haploidentical transplant.